Canatu (CANATU) Company Presentation summary

Transaction overview and structure

• Lifeline SPAC I will acquire all shares in Canatu via a 100% share exchange, with Canatu receiving up to €105.6M in primary capital and a fixed enterprise value of €230M, plus earn-outs tied to share price milestones.

• Post-transaction, Canatu will be listed on the First North Growth Market, with a lock-up period for management and key shareholders to maintain alignment.

• The transaction is designed to support Canatu’s growth strategy, leveraging Lifeline SPAC I’s capital and expertise.

• Key dates include transaction announcement on July 5, 2024, EGM approval on August 23, 2024, and listing on September 17, 2024.

Business model and technology

• Canatu specializes in advanced carbon nanotube (CNT) technology, with applications in semiconductor, automotive, and medical diagnostics.

• The company operates two main business models: recurring product sales (e.g., CNT membranes, sensors, film heaters) and equipment/licensing sales (e.g., CNT reactors, royalties).

• Canatu’s dry deposition CNT technology offers significant advantages over wet dispersion, including lower manufacturing costs, superior material properties, and easier customization.

• The company holds 130 patents with over 50 pending, supporting a strong competitive moat in a high-barrier-to-entry market.

Market focus and growth prospects

• Semiconductor is the current core focus, accounting for 80% of 2023 revenue, with CNTs used in EUV pellicles and inspection membranes essential for advanced chip manufacturing.

• Automotive applications (20% of 2023 revenue) include film heaters for LiDAR and cameras, supporting advanced driver assistance and autonomous driving.

• Medical diagnostics is an emerging focus, leveraging CNT-based biosensors for highly sensitive, rapid point-of-care (POC) testing.

• Addressable markets in these sectors are projected to grow to €2–4 billion by 2030, with strong drivers from AI, consumer electronics, EVs, and healthcare trends.